Teva Faces EU Antitrust Probe Over MS Drug Patent Strategy
European enforcers are investigating Teva over concerns the pharmaceutical company delayed the emergence of generic competitors to its blockbuster multiple sclerosis drug Copaxone by misusing patent procedures and disparaging rivals....To view the full article, register now.
Already a subscriber? Click here to view full article